• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical launches Fantom in Switzerland with first implant of bioresorbable scaffold

October 16, 2017 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) has expanded its commercial operations into Switzerland, the company said today, with the first implant of its Fantom bioresorbable scaffold.

The scaffold is made from Reva’s tyrosine-derived, radiopaque polymer, rendering Fantom visible under fluoroscopy – a characteristic that is unique to Reva’s product.

Fantom also sports 125 micron struts, which have held up in clinical trials. Data from the Fantom II study showed that Reva’s product helped maintain vessel patency after six and nine months with 0% malapposition and 99% strut coverage.

“Following my experience with Fantom, I have been able to see first-hand how Fantom’s technology with the Tyrocore polymer offers simplified deliverability, single-step inflation for ease of use, and radiopacity for accurate scaffold placement,” Dr. Gregor Leibundgut, who implanted the device, said in prepared remarks.

“Bioresorbable scaffolds have the potential to offer comparable short-term treatment without the long-term complications of a permanent metallic stent. This is an important treatment option and we are happy to offer it to our patients.”

“Fantom, made with Reva’s novel polymer called Tyrocore, is an exciting advancement in bioresorbable scaffold technology that has the potential to positively impact clinical practice for physicians and patients,” CEO Reggie Groves added. “With the launch of Fantom in Switzerland, Reva continues to execute on our growth plan with direct selling efforts in the first phase of Fantom’s targeted launch.”

In a study published in the September issue of JACC: Cardiovascular Intervention, Reva’s Fantom product succeeded after six months.

The sirolimus-eluting device was studied with 117 patients with single de novo native coronary artery lesions. The primary angiographic endpoint was mean late lumen loss at six months. The study’s primary clinical endpoint was major adverse cardiac events at six months, including cardiac death, myocardial infarction or clinically driven target lesion revascularization.

Short-term technical success, short-term procedural success and clinical procedural success was met in 96.6%, 99.1% and 99.1% of participants, the authors reported. The mean in-stent late lumen loss was 0.25 millimeters (+/- 0.40) after six months. The team reported observing binary restenosis in two patients.

Major adverse cardiac events happened in three patients within the six-month study period, including two myocardial infarctions and two target lesion revascularizations.

Scaffold thrombosis was seen in one patient, the team added.

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS